Evolving practices, treatment decisions, and unmet needs in intermediate-stage hepatocellular carcinoma: An Asia Pacific perspective

doi:10.4251/wjgo.121745

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 10

This Article

(7)

(0)

(56)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastrointest Oncol. Oct 15, 2026; 18(10): 121745
Published online Oct 15, 2026. doi: 10.4251/wjgo.121745

Table 8 Experience of using systemic therapies in combination/sequence with locoregional therapy for the treatment of intermediate-stage hepatocellular carcinoma among all Asia Pacific prescribers (n = 54)

	Lenvatinib	Sorafenib	Pembrolizumab + lenvatinib	Atezolizumab + bevacizumab	Durvalumab + bevacizumab	Durvalumab + tremelimumab	Other	None of the above
Respondents with experience of using systemic therapy in combination/sequence with LRT, n (%)	51 (94.4)	24 (44.4)	14 (25.9)	37 (68.5)	11 (20.4)	19 (35.2)	3 (5.6)	1 (1.9)
LRTs used in combination with systemic therapy, n/N (%)
C-TACE	43/47 (91.5)	17/18 (94.4)	11/12 (91.7)	28/32 (87.5)	9/10 (90.0)	14/18 (77.8)	-	-
DEB-TACE	20/47 (42.6)	6/18 (33.3)	6/12 (50.0)	15/32 (46.9)	2/10 (20.0)	10/18 (55.6)	-	-
TARE	7/47 (14.9)	3/18 (16.7)	1/12 (8.3)	11/32 (34.4)	-	1/18 (5.6)	-	-
Other radiotherapy	8/47 (17.0)	2/18 (11.1)	1/12 (8.3)	6/32 (18.8)	-	1/18 (5.6)	-	-
Ablation	10/47 (21.3)	2/18 (11.1)	1/12 (8.3)	11/32 (34.4)	1/10 (10.0)	2/18 (11.1)	-	-
Timing of systemic therapy use in relation to TACE, n/N (%)
Pre-TACE	14/44 (31.8)	3/17 (17.6)	4/12 (33.3)	7/31 (22.6)	-	4/16 (25.0)	-	-
Peri-TACE	16/44 (36.4)	7/17 (41.2)	3/12 (25.0)	5/31 (16.1)	4/10 (40.0)	5/16 (31.3)	-	-
Post-TACE	12/44 (27.3)	6/17 (35.3)	4/12 (33.3)	18/31 (58.1)	6/10 (60.0)	6/16 (37.5)	-	-
Other	2/44 (4.5)	1/17 (5.9)	1/12 (8.3)	1/31 (3.2)	-	1/16 (6.3)	-	-

LRT: Locoregional therapy; C-TACE: Conventional transarterial chemoembolization; DEB-TACE: Drug-eluting beads transarterial chemoembolization; TARE: Transarterial radioembolization; TACE: Transarterial chemoembolization.

Full Size Table

Citation: Tanasanvimon S, Cheng PN, Kang W, Ho GF, Pham TA, Cabato M, Husni RE, Kim BY, Chow P. Evolving practices, treatment decisions, and unmet needs in intermediate-stage hepatocellular carcinoma: An Asia Pacific perspective. World J Gastrointest Oncol 2026; 18(10): 121745
URL: https://www.wjgnet.com/1948-5204/full/v18/i10/121745.htm
DOI: https://dx.doi.org/10.4251/wjgo.121745

Tanasanvimon S, Cheng PN, Kang W, Ho GF, Pham TA, Cabato M, Husni RE, Kim BY, Chow P. Evolving practices, treatment decisions, and unmet needs in intermediate-stage hepatocellular carcinoma: An Asia Pacific perspective. World J Gastrointest Oncol 2026; 18(10): 121745 [DOI: 10.4251/wjgo.121745]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.